Ranbaxy may have to pay huge fine, again
Ranbaxy Laboratories, set to be merged with Sun Pharmaceutical Industries, might again have to pay a hefty penalty to the US authorities for alleged violations at its Toansa factory in Punjab. The facility
Ranbaxy Pharmaceuticals
-
Ranbaxy malaria drug in final trial stage
May be the first new chemical entity developed and marketed by an Indian company. Malvinder singhSix years after the Geneva-based, not-for-profit organisation, Medicines for Malaria Venture (MMV), made Ranbaxy its drug development partner, the latter today announced the start of final-stage clinical trials for a new anti-malaria drug.
-
Ranbaxy close to completing trials for new malaria drug
New Delhi, May 4 Ranbaxy Laboratories Ltd on Monday announced the commencement of the third phase clinical trials for its new anti-malaria combination drug in India, Bangladesh and Thailand.
-
Indian pharma emerges big player in Japan
PB Jayakumar / Mumbai May 2, 2009, 0:14 IST Tokyo's policy push for generics an added draw. Leading Indian drug makers such as Ranbaxy, Lupin, Zydus Cadila and Dishman, which forayed into Japan in the past three years, have emerged as important players in the generic or copycat drug business of patented medicines in that market, the second largest in the world.
-
Cipla, Ranbaxy to reap flu gains
PAWAN BALI The spread of Swine flu is likely to boost the sales of companies like Cipla, which can provide drugs and vaccines for this deadly disease. Ms Sarabjit Kaur Nagra, pharma analyst with Angel Broking said that Cipla and Ranbaxy are the two Indian companies, which can provide drugs to deal with Swine flu.
-
Ranbaxy's Paonta plant gets nod from UK, Australia regulators
Ranbaxy Laboratories
-
Australia approves Ranbaxy drug
New Delhi: Ranbaxy announced on Friday that it has received approval from Australia
-
Ranbaxy uses US arm to stay in the race
Joe C Mathew / New Delhi March 06, 2009, 0:37 IST
-
US move to hit key drugs: Ranbaxy
DAIICHI Sankyo, the new owner of India
-
Ranbaxy barred
After the US, New Zealand alert indian drug manufacturer Ranbaxy Laboratories